# Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

> **NCT04468100** · PHASE3 · COMPLETED · sponsor: **AO GENERIUM** · enrollment: 100 (actual)

## Conditions studied

- Cystic Fibrosis
- Fibrosis

## Interventions

- **BIOLOGICAL:** Tigerase®
- **BIOLOGICAL:** Pulmozyme®

## Key facts

- **NCT ID:** NCT04468100
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-30
- **Primary completion:** 2018-05-16
- **Final completion:** 2018-05-16
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04468100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04468100, "Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04468100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*